The data of national medical interview on hyperprolactinemia treatment in real clinical practice
https://doi.org/10.14341/omet2016214-19
Abstract
Hyperprolactinemia is one of the most common endocrine pathology, which doctors of different specialties face in real clinical practice.
Aim of the study was to determine the features of management and treatment of patients with hyperprolactinemia in different regions of Russian Federation.
Material and methods. The national medical interview on hyperprolactinemia treatment was conducted in 2014-2015 among 74 endocrinologists from 30 regions of Russia.
Results. Endocrinologists in regions of Russian Federation have satisfactory access to various methods of diagnostics of the disease and its complications, knowledge of different dopamine agonists for treatment, and have practice in management of patients with drug-induced hyperprolactinemia.
Conclusion. According the data of the interview majority of doctors have insufficient level of knowledge in management and treatment of patients with hyperprolactinemia that is why additional lectures and seminars should be conducted by specialists of that problem.
About the Authors
Galina A. Melnichenko
Endocrinology Research Centre
Russian Federation
Competing Interests: No conflict of interest
Russian Federation
MD, PhD, Professor
Competing Interests: No conflict of interest
Larisa K. Dzeranova
Endocrinology Research Centre
Russian Federation
Competing Interests: No conflict of interest
Russian Federation
MD, PhD
Competing Interests: No conflict of interest
Ekaterina A. Pigarova
Endocrinology Research Centre
Russian Federation
Competing Interests: No conflict of interest
Russian Federation
MD, PhD
Competing Interests: No conflict of interest
Svetlana Y. Vorotnikova
Endocrinology Research Centre
Russian Federation
Competing Interests: No conflict of interest
Russian Federation
MD, PhD
Competing Interests: No conflict of interest
Tatiana S. Tarasova
Endocrinology Research Centre
Russian Federation
Competing Interests: No conflict of interest
Russian Federation
MD, PhD
Competing Interests: No conflict of interest
References
1. Дзеранова Л.К. Гиперпролактинемия. В кн.: Клиническая нейроэндокринология / Под ред. И.И. Дедова. – М.: УП Принт; 2011. – с. 49. [Dzeranova LK. Hyperprolactinemia. In: Clinical neuroendocrinology. Ed by Dedov II. Moscow: UP Print; 2011.р 49 (In Russ)].
2. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. – Тверь: Триада, 2004. [Dedov II, Melnichenko GA, Romantsova TI. Sindrom giperprolaktinemii. Tver: Triada; 2004. (In Russ).]
3. Романцова Т.И. Репродукция и энергетический баланс: интегративная роль пролактина // Ожирение и метаболизм. – 2014. – № 1 – С. 5-18. [Romantsova TI. Reproduction and energy balance: the integrative role of prolactin. Obesity and metabolism. 2014;11(1):5-18. (In Russ).] doi: 10.14341/omet201415-18
4. Auriemma RS, Granieri L, Galdiero M, et al. Effect of Cabergoline on Metabolism in Prolactinomas. Neuroendocrinology. 2013;98(4):299-310. doi: 10.1159/000357810.
5. Ciresi A, Amato MC, Guarnotta V, et al. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. ClinEndocrinol (Oxf). 2013;79(6):845-52. doi: 10.1111/cen.12204.
6. Inancli S, Usluogullari A, Ustu Y, et al. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine. 2013;44(1):193-9. doi: 10.1007/s12020-012-9857-y.
7. Kars M, Souverein PC, Herings RM, et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. JCEM. 2009;94(8):2729-34. doi: 10.1210/jc.2009-0177.
8. Мельниченко Г.А., Дзеранова Л.К., Дедов И.И. и др. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения гиперпролактинемии // Проблемы эндокринологии. – 2013. – Т. 59. - №6. – С. 19-26. [Melnichenko GA, Dzeranova LK, Dedov II. Federal clinical recommendation on clinic, diagnostics, differential diagnosis and treatment of hyperprolactinemia. Problems of endocrinology.2013;59(6):19-26 (In Russ).] doi:10.14341/probl201359619-26
9. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. JCEM. 2011;96(2):273-88. doi:10.1210/jc.2010-1692.
10. Rabinovich I, Cámara R, García M, et al. Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia. Endocrinol Nutr. 2013;60(6):308-19. doi:10.1016/j.endonu.2012.11.005.
11. Molitch ME. Prolactinoma in pregnancy Best Pract Res Clin Endocrinol Metab. 2011;25(6):885-96. doi: 10.1016/j.beem.2011.05.011.
Review
For citations:
Melnichenko G.A., Dzeranova L.K., Pigarova E.A., Vorotnikova S.Y., Tarasova T.S. The data of national medical interview on hyperprolactinemia treatment in real clinical practice. Obesity and metabolism. 2016;13(2):14-19. (In Russ.) https://doi.org/10.14341/omet2016214-19
Views:
919
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
